Search

Displaying results 1611 - 1620 of 7498 in total
  1. Drug

    Telmisartan

    go.drugbank.com/drugs/DB00966
    ApprovedInvestigational

    smooth muscle, ultimately leading to a reduction in arterial blood pressure. … Generally, angiotensin II receptor blockers (ARBs) such as telmisartan bind to the angiotensin II type 1 (AT1) receptors with high affinity, causing inhibition of the action of angiotensin II on vascular

    Mixtures: CO-TELSARIL 80/12,5, CO-TELSARIL 40/12,5Categories: Agents Acting on the Renin-Angiotensin System
  2. Drug

    Phenindione

    go.drugbank.com/drugs/DB00498
    ApprovedInvestigational

    Phenindione has actions similar to warfarin, but it is now rarely employed because of its higher incidence of severe adverse effects. (From Martindale, The Extra Pharmacopoeia, 30th ed, p234)

  3. Drug

    Moxonidine

    go.drugbank.com/drugs/DB09242
    ApprovedInvestigationalWithdrawn

    It is suggested to be effective in cases where other agents such as thiazides, beta-blockers, ACE inhibitors, and calcium channel blockers are not appropriate or irresponsive. … As well, moxonidine has been shown to present blood pressure-independent beneficial effects on insulin resistance syndrome.

  4. Drug

    Plasma protein fraction (human)

    go.drugbank.com/drugs/DB13968
    ApprovedInvestigational

    [A32512] It is already reviewed under the category of biologics by the FDA where the processing, required tests, requirements and labeling are incorporated. … The composition of PPFh should be 5% of protein from which 83% should consist of albumin and no more of 17% should be globulin.

    Products: OCTAPLAS Blood Group O
  5. Drug

    Quinupristin

    go.drugbank.com/drugs/DB01369
    Approved

    Quinupristin/dalfopristin is a combination of two antibiotics used to treat infections by staphylococci and by vancomycin-resistant Enterococcus faecium.

  6. Drug

    Dihydroergotamine

    go.drugbank.com/drugs/DB00320
    ApprovedInvestigational

    [L38469] Its use has largely been supplanted by triptans in current therapy due to the class's greater selectivity and more favourable side effect profile. … [A239569] The recently approved Precision Olfactory Delivery technology developed by Impel Neuropharma technology has correlated with an increase of 3-fold in Cmax and 4-fold in AUC despite the solution

    Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin SyndromeSynonyms: (2R,4R,7R)-N-[(1S,2S,4R,7S)-7-benzyl-2-hydroxy-4-methyl-5,8-dioxo-3-oxa-6,9-diazatricyclo[7.3.0.02,6]dodecan-4-yl]-6-methyl-6,11-diazatetracyclo[7.6.1.02,7.012,16]hexadeca-1(16),9,12,14-tetraene-4-carboxamide
  7. Drug

    Voxelotor

    go.drugbank.com/drugs/DB14975
    Approved

    [L10403] It was developed by Global Blood Therapeutics, Inc. … to 20 million others worldwide.

  8. Target

    Inactive phospholipase C-like protein 1

    go.drugbank.com/bio_entities/BE0001081
    TargetHumans

    Shows no PLC activity to phosphatidylinositol 4,5-bisphosphate and phosphatidylinositol. Component in the phospho-dependent endocytosis process of GABA A receptor (By similarity).

    Synonyms: Phospholipase C-related but catalytically inactive protein
  9. Drug

    Insulin lispro

    go.drugbank.com/drugs/DB00046
    ApprovedInvestigational

    cells that the body is no longer able to produce insulin on its own. … in position B29 is replaced by proline.

  10. Drug

    Pegunigalsidase alfa

    go.drugbank.com/drugs/DB14992
    ApprovedInvestigational

    Pegunigalsidase alfa (PRX-102) is a recombinant form of human α-galactosidase-A indicated for long-term enzyme replacement therapy in patients with Fabry disease, a rare genetic disorder characterized by … While agalsidase alfa and agalsidase beta enter lysosomes via the mannose-6-phosphate (M6P) receptor, pegunigalsidase alfa carries no M6P on its glycans and does not depend on the M6P receptor during cellular